University of SaskatchewanHARVEST
  • Login
  • Submit Your Work
  • About
    • About HARVEST
    • Guidelines
    • Browse
      • All of HARVEST
      • Communities & Collections
      • By Issue Date
      • Authors
      • Titles
      • Subjects
      • This Collection
      • By Issue Date
      • Authors
      • Titles
      • Subjects
    • My Account
      • Login
      JavaScript is disabled for your browser. Some features of this site may not work without it.
      View Item 
      • HARVEST
      • Electronic Theses and Dissertations
      • Graduate Theses and Dissertations
      • View Item
      • HARVEST
      • Electronic Theses and Dissertations
      • Graduate Theses and Dissertations
      • View Item

      Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor

      Thumbnail
      View/Open
      KARKARE-THESIS-2017.pdf (6.304Mb)
      Date
      2019-09-19
      Author
      Karkare, Sharayu A 1993-
      ORCID
      0000-0002-9760-5924
      Type
      Thesis
      Degree Level
      Masters
      Metadata
      Show full item record
      Abstract
      Osteosarcoma (OS) represents 3.4% of all childhood cancers with overall survival of 70% not improving in 30 years. The consistent surface overexpression of insulin-like growth factor-2 receptor (IGF2R) has been reported in commercial and patient-derived xenograft (PDX) OS cell lines. We aimed to assess efficacy and safety of treating PDX and commercial OS tumors in mice with radiolabeled antibody to IGF2R. IGF2R expression on human commercial lines 143B and SaOS2 and PDX lines OS-17, OS-33 and OS-31 was evaluated by FACS. The biodistribution and microSPECT/CT imaging with 111Indium-2G11 mAb was performed in 143B and OS-17 tumor-bearing SCID mice and followed by radioimmunotherapy (RIT) with 177Lutetium-l2G11 and safety evaluation. All OS cell lines expressed IGF2R. Biodistribution and microSPECT/CT revealed selective uptake of 2G11 mAb in 143B and OS17 xenografts. RIT significantly slowed down the growth of OS17 and 143B tumors without local and systemic toxicity. This study demonstrates the feasibility of targeting IGF2R on OS in PDX and sets the stage for further development of RIT of O
      Degree
      Master of Science (M.Sc.)
      Department
      Pharmacy and Nutrition
      Program
      Pharmacy
      Supervisor
      Dadachova, Kate
      Committee
      Phenix, Chris; Uppalapati, Maruti; Badea, Ildiko; Price, Eric
      Copyright Date
      September 2017
      URI
      http://hdl.handle.net/10388/12331
      Subject
      RIT, OS, IGF2R, SPECT-CT, TRT, mAb, Lutetium-177, Actinium-225, PDX, SCID
      Collections
      • Graduate Theses and Dissertations
      University of Saskatchewan

      University Library

      The University of Saskatchewan's main campus is situated on Treaty 6 Territory and the Homeland of the Métis.

      © University of Saskatchewan
      Contact Us | Disclaimer | Privacy